BioCentury | Aug 6, 2020
Emerging Company Profile

T-knife: creating TCR factories with transgenic mice

Armed with a €66 million ($78.2 million) series A round, T-knife emerged from stealth Thursday with plans to bring four TCR therapies into clinical testing by 2022 using a transgenic mouse platform designed to generate...
BioCentury | Apr 3, 2020
Deals

Janssen takes another shot at off-the-shelf CAR Ts with Fate deal

Janssen is adding an off-the-shelf CAR-T and CAR-NK technology to build out its cancer cell therapy pipeline through a deal with Fate Therapeutics, marking at least the second time the company has partnered for allogeneic...
BioCentury | Mar 19, 2020
Emerging Company Profile

OncoOne: targeting oxidized MIF for solid tumors

A trio of Shire veterans launched OncoOne on Wednesday with a €13 million series A round and a batch of biologics against oxidized MIF, a highly selective tumor antigen that was abandoned by the pharma...
BioCentury | Feb 28, 2020
Emerging Company Profile

Lava: better safety for bispecifics with γδ T cell engagement

...domain antibody fragment (VHH) to engage the TCR, while a second VHH targets a specific tumor-associated antigen...
BioCentury | Jan 14, 2020
Clinical News

Complete response to NK cell therapy prompts NantKwest to plan pivotal trials

...combination included N-803, anti-PD-L1 mAb Bavencio avelumab, low-dose metronomic chemoradiation therapy and adenoviral and yeast tumor-associated antigen...
BioCentury | Nov 19, 2019
Company News

Nov. 19 Company Quick Takes: Medicines Co. gains on buyout rumor; plus Samsung's biosimilar under review and Zelluna-Glycostem

Medicines Co. mum on Novartis takeout rumor The Medicines Co. (NASDAQ:MDCO) declined to comment to BioCentury on a Bloomberg report that said Novartis AG (NYSE:NVS; SIX:NOVN) is among several companies exploring an acquisition of the...
BioCentury | Nov 1, 2019
Emerging Company Profile

Tmunity: Manufacturing momentum for CAR and TCR therapies

...to lack PD-1 and endogenous TCRα and TCRβ chains, and express a TCR against the tumor-associated antigen...
BioCentury | Oct 11, 2019
Product Development

What’s next for neoantigens

With Phase I data trickling in for first-generation vaccines, neoantigen companies are now pursuing new modalities, including cell therapy, and developing tools to expand the target space. Over a dozen companies have launched programs to...
BioCentury | Sep 13, 2019
Emerging Company Profile

Valo: adding tumor antigens to oncolytic viruses

With platforms that can rapidly display tumor-specific antigens on oncolytic viruses without genetic engineering, Valo is positioning itself as an attractive collaborator for immuno-oncology companies. Oncolytic viruses kill cancer cells by lysing the cells, and...
BioCentury | Jul 9, 2019
Financial News

BioNTech broadens investor base with $325M B round

While BioNTech remains quiet about a timeline for a potential listing, the German biotech has further broadened its investor base with multiple Asia-Pacific firms backing a $325 million series B round as it invests in...
Items per page:
1 - 10 of 259